Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide
The aims of this study were to investigate the effects of CYP2C9 and CYP2C19 polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in healthy Chinese subjects.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Study the Effects of CYP2C9 and CYP2C19 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide in Healthy Chinese Subject|
The whole blood samples of each person are stored at -80℃.
|Study Start Date:||August 2008|
|Study Completion Date:||December 2008|
CYP2C9*1/*1 and CYP2C19*1/*1 alleles carrier
CYP2C19 PMs (CYP2C19*2/*2, CYP2C19*2/*3 or CYP2C19*3/*3)
CYP2C9*1/*3 and CYP2C19*1/*1 alleles carrier
Compared with CYP2C19, CYP2C9 polymorphism appears to have a dominant role in glipizide pharmacokinetics and pharmacodynamics in vivo. This indicated that dose adjustment based on CYP2C9 genotype may improve antidiabetic treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00806013
|The second hospital to Liaoning University of TCM|
|Shenyang, Liaoning, China, 201203|
|Principal Investigator:||Bo Tan||Shanghai Institute of Materia Medica, Chinese Academy of Sciences|